JP2012176953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012176953A5 JP2012176953A5 JP2012087648A JP2012087648A JP2012176953A5 JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5 JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012087648 A JP2012087648 A JP 2012087648A JP 2012176953 A5 JP2012176953 A5 JP 2012176953A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- fragment
- kir2dl1
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (20)
- ヒトＫＩＲ２ＤＬ１およびヒトＫＩＲ２ＤＬ２／３と交叉反応する、抗ＫＩＲ抗体またはその抗体断片であって、
（ａ）ＫＩＲ２ＤＳ４と結合しないか；
（ｂ）アミノ酸残基１０５，１０６，１０７，１０８，１０９，１１０，１１１，１２７，１２９，１３０，１３１，１３２，１３３，１３４，１３５，１５２，１５３，１５４，１５５，１５６，１５７，１５８，１５９，１６０，１６１，１６２，１６３，１８１および１９２によって規定されるエピトープ領域内において、ヒトＫＩＲ２ＤＬ１と結合するか；
（ｃ）Ｒ１３１がＡｌａによって置換されているヒトＫＩＲ２ＤＬ１の変異体と結合しないか；
（ｄ）Ｒ１５７がＡｌａによって置換されているヒトＫＩＲ２ＤＬ１の変異体と結合しないか；
（ｅ）Ｒ１５８がＡｌａによって置換されているヒトＫＩＲ２ＤＬ１の変異体と結合しないか；
（ｆ）ヒトＫＩＲ２ＤＬ１残基１３１、１５７および１５８に結合するか；または
（ｇ）Ｒ１３１がＴｒｐによって置換されているヒトＫＩＲ２ＤＳ３の変異体と結合するものの、野生型ＫＩＲ２ＤＳ３と結合せず、
ここにおいて、前記抗体またはその断片は、ヒトＫＩＲ２ＤＬ１および／またはヒトＫＩＲ２ＤＬ２／３によって媒介されるＮＫ細胞の細胞毒性の阻害を減少させ、中和しおよび／または逆転させ；および
ここにおいて、前記抗体断片は、Ｆａｂ断片、Ｆ（ａｂ’）２断片、Ｆｖ断片、Ｆ（ａｂ’）断片、二重特異性抗体および一本鎖抗体（ＳｃＦｖ）から選択される
抗ＫＩＲ抗体またはその抗体断片。 - ＫＩＲ２ＤＬ１および／またはＫＩＲ２ＤＬ２／３ヒト受容体への結合に関して、ＤＦ２００、１−７Ｆ９またはＮＫＶＳＦ１抗体と競合する請求項１に記載の抗体または抗体断片。
- ＫＩＲ２ＤＬ１ヒト受容体への結合に関して、ＥＢ６抗体と競合する請求項１に記載の抗体または抗体断片。
- ＫＩＲ２ＤＬ２／３ヒト受容体への結合に関して、ＧＬ１８３抗体と競合する請求項１に記載の抗体または抗体断片。
- 配列番号１または配列番号２に示されるアミノ酸配列を有する軽鎖可変領域を含む請求項１に記載の抗体または抗体断片。
- 配列番号３、配列番号４、配列番号５、配列番号６、配列番号７または配列番号８に示されるアミノ酸配列を有する１以上の軽鎖ＣＤＲを含む請求項１に記載の抗体または抗体断片。
- 配列番号９に示されるアミノ酸配列を有する重鎖可変領域を含む請求項１に記載の抗体または抗体断片。
- 配列番号１０、配列番号１１または配列番号１２に記載のアミノ酸配列を有する１以上の重鎖ＣＤＲを含む請求項１に記載の抗体または抗体断片。
- キメラ抗体、ヒト抗体またはヒト化抗体である請求項１から８の何れか１項に記載の抗体または抗体断片。
- トキシン、検出可能な部分、放射性同位体、造影剤または固相支持体に抱合されているか、または共有結合されている請求項１から８の何れか１項に記載の抗体または抗体断片を含む誘導体。
- ヒトＫＩＲ２ＤＬ１およびヒトＫＩＲ２ＤＬ２／３と交叉反応し、そのようなＫＩＲの阻害活性を中和する抗ＫＩＲ抗体または抗体断片であって、前記抗体は、ＫＩＲ２ＤＬ１および／またはＫＩＲ２ＤＬ２／３ヒト受容体への結合に関してＤＦ−２００抗体（寄託番号ＣＮＣＭ Ｉ−３２２４）と競合する抗体または抗体断片。
- 図１２に示される配列を有するＰａｎ２Ｄの軽鎖可変領域を含む請求項１１に記載の抗体または抗体断片。
- 図１２に示される配列を有するＰａｎ２Ｄの１以上の軽鎖可変領域ＣＤＲを含む請求項１１に記載の抗体または抗体断片。
- 図１２に示される配列を有するＰａｎ２Ｄの全ての軽鎖可変領域ＣＤＲを含む請求項１１に記載の抗体または抗体断片。
- 前記抗体はＰａｎ２Ｄである請求項１１に記載の抗体または抗体断片。
- （ａ）ＫＩＲ２ＤＳ４に結合せず、
（ｂ）アミノ酸残基１０５，１０６，１０７，１０８，１０９，１１０，１１１，１２７，１２９，１３０，１３１，１３２，１３３，１３４，１３５，１５２，１５３，１５４，１５５，１５６，１５７，１５８，１５９，１６０，１６１，１６２，１６３，１８１および１９２によって規定されるエピトープ領域内でヒトＫＩＲ２ＤＬ１に結合し、
（ｃ）Ｒ１３１がＡｌａで置換されているヒトＫＩＲ２ＤＬ１の変異体に結合せず、
（ｄ）Ｒ１５７がＡｌａで置換されているヒトＫＩＲ２ＤＬ１の変異体に結合せず、
（ｅ）Ｒ１５８がＡｌａで置換されているヒトＫＩＲ２ＤＬ１の変異体に結合せず、
（ｆ）ヒトＫＩＲ２ＤＬ１残基１３１，１５７および１５８に結合し、または
（ｇ）Ｒ１３１がＴｒｐで置換されているヒトＫＩＲ２ＤＳ３の変異体に結合するが、野生型ＫＩＲ２ＤＳ３に結合しない
請求項１１に記載の抗体または抗体断片。 - ＫＩＲ２ＤＬ１ヒト受容体への結合についてＥＢ６抗体と競合する請求項１１から１６の何れか１項に記載の抗体または抗体断片。
- ＫＩＲ２ＤＬ２／３ヒト受容体への結合についてＧＬ１８３抗体と競合する請求項１１から１７の何れか１項に記載の抗体または抗体断片。
- キメラ抗体、ヒト抗体またはヒト化抗体である請求項１１から１８の何れか１項に記載の抗体または抗体断片。
- 前記抗体断片は、Ｆａｂ断片、Ｆ（ａｂ’）２断片、Ｆｖ断片、Ｆ（ａｂ’）断片、二重特異性抗体、一本鎖抗体（ＳｃＦｖ）から成る群から選択される１つである請求項１１から１９の何れか１項に記載の抗体または抗体断片。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48389403P | 2003-07-02 | 2003-07-02 | |
| US60/483,894 | 2003-07-02 | ||
| US54547104P | 2004-02-19 | 2004-02-19 | |
| US60/545,471 | 2004-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Division JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Division JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012176953A JP2012176953A (ja) | 2012-09-13 |
| JP2012176953A5 true JP2012176953A5 (ja) | 2013-04-18 |
| JP5826697B2 JP5826697B2 (ja) | 2015-12-02 |
Family
ID=33567703
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Active JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2006516606A Active JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
| JP2012087648A Active JP5826697B2 (ja) | 2003-07-02 | 2012-04-06 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2015042824A Active JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515738A Active JP5015592B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2006516606A Active JP4871125B2 (ja) | 2003-07-02 | 2004-07-01 | Ｎｋ細胞活性を調節するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042824A Active JP6556465B2 (ja) | 2003-07-02 | 2015-03-04 | Ｎｋ細胞活性を制御するための組成物及び方法 |
| JP2018078329A Pending JP2018153185A (ja) | 2003-07-02 | 2018-04-16 | Ｎｋ細胞活性を制御するための組成物及び方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9902936B2 (ja) |
| EP (3) | EP1673397B1 (ja) |
| JP (5) | JP5015592B2 (ja) |
| KR (5) | KR101325023B1 (ja) |
| CN (2) | CN103588880B (ja) |
| AT (1) | ATE490984T1 (ja) |
| AU (2) | AU2004253630B2 (ja) |
| BR (2) | BRPI0412138B8 (ja) |
| CA (2) | CA2530591A1 (ja) |
| CY (1) | CY1113394T1 (ja) |
| DE (1) | DE602004030464D1 (ja) |
| DK (2) | DK1673397T3 (ja) |
| ES (2) | ES2725526T3 (ja) |
| HK (1) | HK1091662A1 (ja) |
| HR (1) | HRP20120845T1 (ja) |
| IL (3) | IL172613A (ja) |
| MX (1) | MXPA05013923A (ja) |
| NO (4) | NO338818B1 (ja) |
| PL (1) | PL1639013T3 (ja) |
| PT (1) | PT1639013E (ja) |
| RU (2) | RU2376315C2 (ja) |
| WO (2) | WO2005003168A2 (ja) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| HUE033129T2 (en) | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
| EP1740619A1 (en) * | 2004-04-30 | 2007-01-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as nk-type ldgl |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| TWI472338B (zh) * | 2004-07-01 | 2015-02-11 | Novo Nordisk As | 人類抗ｋｉｒ抗體 |
| DK2921500T3 (da) | 2004-07-10 | 2023-09-18 | The Institute For Cancer Res | Genetisk modificerede, humane, naturlige dræbercellelinjer |
| JP5525689B2 (ja) * | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
| EP1835937B1 (en) | 2005-01-06 | 2012-04-11 | Novo Nordisk A/S | Compositions and methods for treating viral infection |
| US8222376B2 (en) | 2005-01-06 | 2012-07-17 | Novo Nordisk A/S | KIR-binding agents and methods of use thereof |
| EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| CN101300272B (zh) * | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| EP2109460B1 (en) * | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| US8709411B2 (en) * | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
| US20120009148A1 (en) * | 2008-12-29 | 2012-01-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| US20120308986A1 (en) * | 2010-02-08 | 2012-12-06 | Biotherapy Institute Of Japan | Method for producing nk cell-enriched blood product |
| BR112013012138B1 (pt) | 2010-11-22 | 2022-02-22 | Innate Pharma Sa | Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir) |
| TWI560200B (en) | 2011-05-25 | 2016-12-01 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
| EP2723362A1 (en) | 2011-06-21 | 2014-04-30 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| WO2013076139A1 (en) * | 2011-11-23 | 2013-05-30 | F. Hoffmann-La Roche Ag | Cd40l expressing mammalian cells and their use |
| JP6507097B2 (ja) * | 2012-09-19 | 2019-04-24 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | Ｋｉｒ３ｄｌ２結合剤 |
| NZ631405A (en) | 2012-10-02 | 2017-01-27 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| JP6654781B2 (ja) * | 2014-08-29 | 2020-02-26 | 国立大学法人北海道大学 | Ｋｉｒ２ｄｓ１に対するモノクローナル抗体 |
| ES2772307T3 (es) | 2014-10-28 | 2020-07-07 | Childrens Univ Hospital Tuebingen | Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir |
| CN115029362A (zh) | 2015-02-06 | 2022-09-09 | 新加坡国立大学 | 核酸、包含其的工程免疫细胞及其生产方法和用途 |
| BR112017021688A2 (pt) | 2015-04-17 | 2018-08-14 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo |
| EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| EP3943098A3 (en) | 2015-07-16 | 2022-05-11 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| AU2016348391A1 (en) * | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
| CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| IL292302B2 (en) | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| JP2019532017A (ja) | 2016-07-14 | 2019-11-07 | フレッド ハッチンソン キャンサー リサーチ センター | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| US11395838B2 (en) | 2016-09-27 | 2022-07-26 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
| BR112019007365A2 (pt) | 2016-10-12 | 2019-07-09 | Univ Texas | métodos e composições para imunoterapia com tusc2 |
| KR20190068602A (ko) | 2016-10-21 | 2019-06-18 | 이나뜨 파르마 | 항-kir3dl2 작용제에 의한 치료 |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| JP7458188B2 (ja) | 2017-03-31 | 2024-03-29 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| CN110573529A (zh) | 2017-04-05 | 2019-12-13 | 韩国生命工学研究院 | 激活nk细胞的融合蛋白、nk细胞和包含其的药物组合物 |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CN107261304A (zh) * | 2017-06-05 | 2017-10-20 | 中国兽医药品监察所 | 一种奶牛的布鲁氏菌病免疫试剂盒及其应用 |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| CN108060137B (zh) * | 2017-12-26 | 2021-07-02 | 博生吉医药科技(苏州)有限公司 | Il7和il21修饰的nk92细胞、制备方法及其应用 |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| AU2019236865A1 (en) | 2018-03-23 | 2020-10-01 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| CN112292145A (zh) | 2018-03-25 | 2021-01-29 | 斯尼普生物群系有限公司 | 治疗和预防微生物感染 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP4268831A3 (en) | 2018-09-12 | 2024-05-22 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
| CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| US20220054524A1 (en) | 2018-12-21 | 2022-02-24 | Onxeo | New conjugated nucleic acid molecules and their uses |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN111424012A (zh) * | 2020-03-30 | 2020-07-17 | 威海市中心医院 | 一种nk细胞培养用的饲养细胞去增殖能力的处理方法 |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| BR112023003553A2 (pt) | 2020-08-31 | 2023-04-04 | Bristol Myers Squibb Co | Assinatura de localização celular e imunoterapia |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| US20240000837A1 (en) * | 2020-12-23 | 2024-01-04 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies |
| EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CN118055840A (zh) | 2021-10-08 | 2024-05-17 | 3M创新有限公司 | 具有调节的刚度、减小的拉延区和力预算的狭缝模组件 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024026385A1 (en) * | 2022-07-28 | 2024-02-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies |
| WO2024090458A1 (ja) * | 2022-10-25 | 2024-05-02 | 第一三共株式会社 | 抑制型ｋｉｒに対するアゴニストを用いた免疫拒絶の回避方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
| US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5808028A (en) | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
| NZ298145A (en) | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| US6750044B1 (en) | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
| EP1125130B1 (de) * | 1998-10-29 | 2006-07-26 | DakoCytomation Denmark A/S | Nachweis von säure-resistenten mikroorganismen im stuhl |
| NZ514918A (en) | 1999-04-28 | 2003-11-28 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| HUE033129T2 (en) * | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| KR101564713B1 (ko) | 2004-12-28 | 2015-11-06 | 이나뜨 파르마 | Ｎｋｇ2ａ에 대한 단클론 항체 |
| EP1835937B1 (en) * | 2005-01-06 | 2012-04-11 | Novo Nordisk A/S | Compositions and methods for treating viral infection |
| EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| US8222376B2 (en) | 2005-01-06 | 2012-07-17 | Novo Nordisk A/S | KIR-binding agents and methods of use thereof |
| CN101300272B (zh) | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| TWI560200B (en) * | 2011-05-25 | 2016-12-01 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| US9884593B2 (en) * | 2015-02-12 | 2018-02-06 | Pro-Gard Products, Llc | Weapon mounting system |
-
2004
- 2004-07-01 KR KR1020127002275A patent/KR101325023B1/ko active IP Right Grant
- 2004-07-01 MX MXPA05013923A patent/MXPA05013923A/es active IP Right Grant
- 2004-07-01 AT AT04738967T patent/ATE490984T1/de not_active IP Right Cessation
- 2004-07-01 KR KR1020137013482A patent/KR101444717B1/ko active IP Right Grant
- 2004-07-01 BR BRPI0412138A patent/BRPI0412138B8/pt active IP Right Grant
- 2004-07-01 PL PL04744115T patent/PL1639013T3/pl unknown
- 2004-07-01 US US10/563,045 patent/US9902936B2/en active Active
- 2004-07-01 ES ES10178580T patent/ES2725526T3/es active Active
- 2004-07-01 JP JP2006515738A patent/JP5015592B2/ja active Active
- 2004-07-01 DK DK04738967.1T patent/DK1673397T3/da active
- 2004-07-01 KR KR1020067000025A patent/KR20060079180A/ko active Search and Examination
- 2004-07-01 JP JP2006516606A patent/JP4871125B2/ja active Active
- 2004-07-01 CA CA002530591A patent/CA2530591A1/en not_active Abandoned
- 2004-07-01 EP EP04738967A patent/EP1673397B1/en active Active
- 2004-07-01 DK DK04744115.9T patent/DK1639013T3/da active
- 2004-07-01 WO PCT/DK2004/000470 patent/WO2005003168A2/en active Application Filing
- 2004-07-01 PT PT47441159T patent/PT1639013E/pt unknown
- 2004-07-01 EP EP04744115A patent/EP1639013B1/en active Active
- 2004-07-01 RU RU2005140152/13A patent/RU2376315C2/ru active
- 2004-07-01 CN CN201310057089.0A patent/CN103588880B/zh active Active
- 2004-07-01 BR BRPI0412153A patent/BRPI0412153B8/pt active IP Right Grant
- 2004-07-01 AU AU2004253630A patent/AU2004253630B2/en active Active
- 2004-07-01 RU RU2006102960/10A patent/RU2404993C2/ru active
- 2004-07-01 CN CN201310392765.XA patent/CN103467602B/zh active Active
- 2004-07-01 WO PCT/IB2004/002464 patent/WO2005003172A2/en active Application Filing
- 2004-07-01 KR KR1020067000109A patent/KR101375153B1/ko active IP Right Grant
- 2004-07-01 KR KR1020127013323A patent/KR101420344B1/ko active IP Right Grant
- 2004-07-01 AU AU2004253770A patent/AU2004253770C1/en active Active
- 2004-07-01 DE DE602004030464T patent/DE602004030464D1/de active Active
- 2004-07-01 CA CA2530272A patent/CA2530272C/en active Active
- 2004-07-01 ES ES04744115T patent/ES2393485T3/es active Active
- 2004-07-01 EP EP10178580.6A patent/EP2289939B1/en active Active
-
2005
- 2005-12-15 IL IL172613A patent/IL172613A/en active IP Right Grant
- 2005-12-19 NO NO20056048A patent/NO338818B1/no unknown
- 2005-12-20 IL IL172700A patent/IL172700A/en active IP Right Grant
-
2006
- 2006-02-01 NO NO20060528A patent/NO338255B1/no unknown
- 2006-07-18 HK HK06108029.2A patent/HK1091662A1/xx unknown
-
2012
- 2012-04-06 JP JP2012087648A patent/JP5826697B2/ja active Active
- 2012-10-22 HR HRP20120845TT patent/HRP20120845T1/hr unknown
- 2012-11-28 CY CY20121101151T patent/CY1113394T1/el unknown
-
2015
- 2015-03-04 JP JP2015042824A patent/JP6556465B2/ja active Active
- 2015-04-28 IL IL238490A patent/IL238490A0/en unknown
-
2016
- 2016-02-16 NO NO20160264A patent/NO342318B1/no unknown
- 2016-03-10 NO NO20160411A patent/NO343342B1/no unknown
-
2018
- 2018-01-22 US US15/876,839 patent/US11365393B2/en active Active
- 2018-04-16 JP JP2018078329A patent/JP2018153185A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012176953A5 (ja) | ||
| JP2015163068A5 (ja) | ||
| JP2013198490A5 (ja) | ||
| JP2017048240A5 (ja) | ||
| JP2017052784A5 (ja) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| JP2018516853A5 (ja) | ||
| JP2017114866A5 (ja) | ||
| JP2018510636A5 (ja) | ||
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2017149720A5 (ja) | ||
| JP2009225799A5 (ja) | ||
| HRP20230411T1 (hr) | Dvostruko ciljanje | |
| JP2014205674A5 (ja) | ||
| JP2012502649A5 (ja) | ||
| JP2017504578A5 (ja) | ||
| JP2018520667A5 (ja) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2013506428A5 (ja) | ||
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof | |
| NZ601342A (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| JP2015504421A5 (ja) |